Impedimed Limited · ASX:IPD
Impedimed — Shareholder Meeting (November 2009)
10 slides from Impedimed's shareholder meeting presentation, Nov 23, 2009
Slide 1: ImpediMed Reaffirms Company Growth Prospects (press release)
Monday 23rd November, 2009 ASX : IPD PRESS RELEASE For personal use only IMPEDIMED REAFFIRMS COMPANY GROWTH PROSPECTS At today‟s AGM, Chief Executive Officer, Greg Brown announced to shareholders that the company‟s progress around its US targeted reimbursement program, was positioning the company st
Slide 2: Press release continued: Senate debate and About ImpediMed
driving evidence based medicine. Presently, ImpediMed has the only available FDA cleared device to help establish this requirement,‟ Mr Brown added. Mr Brown went on to also say that the political debate in the US Senate at present is all around why advances in biomedical knowledge and technical inn
Slide 3: ImpediMed AGM CEO Address: 2009 Highlights
For personal use only ImpediMed Limited Surviving cancer without compromising lifestyle ImpediMed AGM CEO Address Greg Brown Mobile 0408 281127 gregbrown@impedimed.com 2009 Highlights • Several new publications – JCO, Cancer, BCRT Validation • Possible ASBS registry & US leg trial • First US cleared
Slide 4: Targeting Multiple Fluid Status Markets
Targeting Multiple Fluid Status Markets For personal use only Lymphoedema market Dialysis market Arms – mainly Breast cancer Licensed by Fresenius Current Fluid Fluid Status Status Market Market Lymphoedema market Oedema market Future Venous insufficiency (VI) Legs – Pelvic cancers ImpediMed
Slide 5: Our Solution - Early Detection, Early Intervention
Our Solution -Early Detection, Early Intervention For personal use only ImpediMed Ltd - Surviving Cancer Without Compromising Lifestyle Key Publication – Cancer May 2008 Preoperative assessment enables the early diagnosis and successful treatment of lymphedema 5 year study assessing lymphedema i
Slide 6: Potential Healthcare Savings – Preemptive Care
Potential Healthcare Savings – Preemptive Care For personal use only MD Anderson/Vanderbilt Economic Study11 • 2 yr estimate of economic burden of breast cancer related lymphoedema (BCRL) • “Psychosocial impact of lymphoedema has been described to be as distressing as the initial diagnosis of BC” •
Slide 7: Lymphoedema – Growing Acceptance Of Issue
Lymphoedema – Growing Acceptance Of Issue For personal use only • Cancer 08 - reduced threat • Most dreaded sequeleae • For Breast cancer lymphoedema • Supports pre-emptive care ImpediMed Ltd - Surviving Cancer Without Compromising Lifestyle Business Momentum 65 L-Dex agreements now in the US mark
Slide 8: Reimbursement Environment
Reimbursement Environment For personal use only Miscellaneous code coverage Women’s Health and Rights act 1998 – mastectomy only Twenty-one similar US state laws The North Carolina state bill was recently signed “Every health benefit plan, as defined in G.S. 58-3-167, shall provide coverag
Slide 9: Why This Product Can Succeed
Why This Product Can Succeed For personal use only • This is breast cancer & don’t tell a patient lymphoedema is not an issue • Strong data supports technology – 15 years of peer reviewed science • Key thought leaders globally helping to drive change – preemptive care • Payers want to decrease chron
Slide 10: Senior Management Expansion
Senior Management Expansion For personal use only Don Myll CFO – San Diego TheraTx (NASDAQ: THTX) co-founder, CFO, VP of Operations - Responsible for all financial and corporate support aspects as company grew from inception to over $400 million in revenue & 8,000 employees in 7 years Peggy Brooker